ライフサイエンスコーパス: insulin resistance

1 h blood pressure, abnormal lipid levels, and insulin resistance).

2 steatosis and severe whole-body and hepatic insulin resistance.

3 oglobin, and homeostasis model assessment of insulin resistance.

4 in the pathogenesis of diet-induced hepatic insulin resistance.

5 ielding triacylglycerol accumulation but not insulin resistance.

6 abetes and homeostatic model of assessment - insulin resistance.

7 ctions between hyperinsulinemia, obesity and insulin resistance.

8 ed beta-cell function relative to peripheral insulin resistance.

9 ion factors but lack glucose intolerance and insulin resistance.

10 s liver and skeletal muscle, contributing to insulin resistance.

11 versed high-fat-diet-induced weight gain and insulin resistance.

12 s impaired insulin clearance coexisting with insulin resistance.

13 of circulating RBP4, even in the setting of insulin resistance.

14 ng, LXR agonist treatment, or obesity-linked insulin resistance.

15 the association between tumour formation and insulin resistance.

16 liver (Ser 307) provided further evidence of insulin resistance.

17 s mice from diet-induced hepatosteatosis and insulin resistance.

18 re protected against age-related obesity and insulin resistance.

19 (VMH) mice displayed glucose intolerance and insulin resistance.

20 ponents independently of central obesity and insulin resistance.

21 ect ectopic lipid accumulation and, thereby, insulin resistance.

22 xes promoting hepatic lipid accumulation and insulin resistance.

23 that begin well before the onset of observed insulin resistance.

24 d fatty acids (NEFAs), ultimately leading to insulin resistance.

25 stant mice and correlated significantly with insulin resistance.

26 2.0 mg/kg body weight of Cd and Hg suggested insulin resistance.

27 alamus, which may contribute to hypothalamic insulin resistance.

28 ed hepatic steatosis, glucose tolerance, and insulin resistance.

29 m atherosclerosis, diet-induced obesity, and insulin resistance.

30 feeding and in the setting of obesity-linked insulin resistance.

31 risk for HCC, based on metabolic factors and insulin resistance.

32 holesteryl ester protein mass or measures of insulin resistance.

33 r endothelial FcgammaRIIB in obesity-induced insulin resistance.

34 d local inflammation, and is associated with insulin resistance.

35 and were protected from HFD-induced systemic insulin resistance.

36 apparently reduce liver fat, but can induce insulin resistance.

37 , play a crucial role in the pathogenesis of insulin resistance.

38 ions where hyperinsulinaemia is secondary to insulin resistance.

39 osely associated with metabolic syndrome and insulin resistance.

40 -/-) mice are protected from weight gain and insulin resistance.

41 with decreased diet-induced weight gain and insulin resistance.

42 ramatic improvement in glucose tolerance and insulin resistance.

43 herapeutic potential in reducing obesity and insulin resistance.

44 plasma LPS levels have been associated with insulin resistance.

45 ischemic stroke in nondiabetic patients with insulin resistance.

46 y lipid-induced event preceding the onset of insulin resistance.

47 fects serum potassium and is associated with insulin resistance.

48 G plays an important role in obesity-induced insulin resistance.

49 sociated with impaired glucose tolerance and insulin resistance.

50 these mice displayed glucose intolerance and insulin resistance.

51 tagonist that creates rapid and long-lasting insulin resistance.

52 d as expected in the setting of diet-induced insulin resistance.

53 onset and progression of obesity-associated insulin resistance.

54 been proposed as a link between obesity and insulin resistance.

55 high-fat diet-induced hepatic steatosis and insulin resistance.

56 for therapeutic development in the field of insulin resistance.

57 epatic lipid storage, energy metabolism, and insulin resistance.

58 ated fasting blood glucose, fatty liver, and insulin resistance.

59 and is associated with ectopic lipid-induced insulin resistance.

60 sure and metabolism with type 2 diabetes and insulin resistance.

61 g obesity to adipose tissue inflammation and insulin resistance.

62 oxidation in the development of obesity and insulin resistance.

63 induced liver steatosis and improves hepatic insulin resistance.

64 of a high fat diet on glucose tolerance and insulin resistance.

65 able option for the treatment of obesity and insulin resistance.

66 tions between maternal factors and offspring insulin resistance.

67 or both at various time points to determine insulin resistance.

68 pletely restored the effect of HFD to induce insulin resistance.

69 ar inflammation along with total, whole-body insulin resistance.

70 s in the insulin receptor results in extreme insulin resistance.

71 adaptation of beta-cells to obesity-induced insulin resistance.

72 for the management of hepatic steatosis and insulin resistance.

73 esity-induced hepatosteatosis and whole body insulin resistance.

74 al microbiota in the etiology of obesity and insulin resistance.

75 nesis to obesity-associated inflammation and insulin resistance.

76 cytokine in the treatment of aging-mediated insulin resistance.

77 ing remained intact despite profound hepatic insulin resistance.

78 12 weeks and exhibit glucose intolerance and insulin resistance.

79 ient overabundance, obesity development, and insulin resistance.

80 o understand the mechanisms in lipid-induced insulin resistance, a more physiological approach is to

81 highest hepatic and serum lipids as well as insulin resistance among the eight studied groups.

82 l infarction among nondiabetic patients with insulin resistance and a recent stroke or transient isch

83 ink between obesity-induced inflammation and insulin resistance and as potential target for treatment

84 Despite evidence of insulin resistance and beta-cell dysfunction in glucose

85 AD), cigarettes smoked per day, lung cancer, insulin resistance and body fat are most negatively corr

86 elatonin secretion, disturbances of glucose, insulin resistance and bone metabolism, and body weight

87 Diabetes and obesity are characterized by insulin resistance and chronic low-grade inflammation.

88 diet (HFD)-induced obesity is accompanied by insulin resistance and compromised brain synaptic plasti

89 uptake ultimately precipitates into cardiac insulin resistance and contractile dysfunction.

90 onents develop and progress in parallel with insulin resistance and could be a clinically relevant pr

91 y processes contribute to obesity-associated insulin resistance and deterioration of glucose metaboli

92 subareas: effects on blood pressure, lipids, insulin resistance and diabetes mellitus, nonalcoholic f

93 (AAAs) have been shown to be associated with insulin resistance and diabetes risk.

94 its capacity to reduce fat mass development, insulin resistance and dyslipidemia in mice.

95 in secretory compensation to obesity-related insulin resistance and dysmetabolism.

96 neate a mechanistic link between obesity and insulin resistance and establish the Them2/PC-TP complex

97 metabolism (homeostasis model assessment of insulin resistance and fasting insulin) through a system

98 f both butyrate-based compounds in reverting insulin resistance and fat accumulation in diet-induced

99 otein kinase II, which promoted both hepatic insulin resistance and gluconeogenesis.

100 ock-out mice are protected from diet-induced insulin resistance and glucose intolerance without accom

101 increased and may act systemically to cause insulin resistance and glucose intolerance.

102 Homeostatic model assessment of insulin resistance and glycosylated hemoglobin were meas

103 ently of body weight, and reduced markers of insulin resistance and hepatic necroinflammation.

104 Hepatic insulin resistance and hepatosteatosis in diet-induced o

105 demonstrates that ILK contributes to hepatic insulin resistance and highlights the previously undefin

106 t diet (HFD)-induced obesity with associated insulin resistance and hyperglycemia.

107 t hyperglycemia and hyperinsulinemia promote insulin resistance and impair lymphatic contractile stat

108 Type 2 diabetes (T2D) is characterized by insulin resistance and impaired insulin secretion, but t

109 cIH is associated with insulin resistance and impaired metabolic homeostasis in

110 nce was attributable to fiber type selective insulin resistance and independent of altered fiber type

111 antly, knockout of Nlrp3 ablated HFD-induced insulin resistance and inflammation in Nrp1(myel-KO) mic

112 mmune system, liver functions and histology, insulin resistance and lipid profile.

113 ity and its associated complications such as insulin resistance and non-alcoholic fatty liver disease

114 ent interaction linking Mg(2+) deficiency to insulin resistance and obesity.

115 ction are key pathophysiological features of insulin resistance and obesity.

116 ding protein 1 (IGFBP-1) are associated with insulin resistance and predict the development of type 2

117 mia improves the adaptation of beta-cells to insulin resistance and represents a protective mechanism

118 iple system atrophy is associated with brain insulin resistance and showed increased expression of th

119 CCDC3 alleviates glucose intolerance, insulin resistance and steatosis formation in transgenic

120 s, thereby promoting obesity-induced hepatic insulin resistance and steatosis.

121 ions in muscle mass, which may contribute to insulin resistance and the development of diabetes.

122 ical element that regulates obesity-mediated insulin resistance and type II diabetes.

123 w model for how foodborne factors can induce insulin-resistance and provide a possible explanation fo

124 resistance (homeostasis model assessment of insulin resistance) and homeostasis model assessment of

125 , C-peptide, homeostasis model assessment of insulin resistance, and blood pressure improved (P < 0.0

126 alth markers, namely obesity, lipid profile, insulin resistance, and blood pressure.

127 luding central adiposity, diabetes mellitus, insulin resistance, and circulating adipokine concentrat

128 active protein, a genetic score representing insulin resistance, and dietary intakes of soft drinks a

129 with this, Fgf21 can rescue Dnmt3a-mediated insulin resistance, and DNA methylation at the FGF21 loc

130 ociated with fetal growth retardation, fetal insulin resistance, and excess adiposity.

131 althy, and yet it induces obesity, diabetes, insulin resistance, and fatty liver in mice.

132 lerance test, fasting plasma insulin levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in

133 (FTI) prevents burn-induced hyperlactatemia, insulin resistance, and increased proteolysis in mouse s

134 ice (db/+) present with glucose intolerance, insulin resistance, and increased weight gain during, bu

135 estosterone, homeostatic model assessment of insulin resistance, and insulin-like growth factor 1.

136 k factors (such as blood pressure elevation, insulin resistance, and lipid derangements), although th

137 eostasis, endocrine and molecular markers of insulin resistance, and organ weights were examined in a

138 eletal muscle inflammation in aging-mediated insulin resistance, and our findings further implicate a

139 Obesity causes insulin resistance, and PPARgamma ligands such as rosigl

140 n rate in response to basal hyperglycemia or insulin resistance, and shows that beta-cell dysfunction

141 food intake and totally prevented adiposity, insulin resistance, and steatosis.

142 ion with increased ectopic lipid deposition, insulin resistance, and type 2 diabetes.

143 Type 2 diabetes and insulin resistance are associated with reduced glucose u

144 Altered energy balance and insulin resistance are important characteristics of agin

145 lectively in endothelium were protected from insulin resistance as a result of the preservation of in

146 pregnancy on maternal glucose tolerance and insulin resistance, as well as, on feto-placental glucos

147 iological changes in HFD-fed mice, including insulin resistance, brain glucose uptake and metabolism,

148 lial IRs accelerated development of systemic insulin resistance but not food intake and obesity.

149 Exercise reduces insulin resistance, but it is not known whether TRPC1 is

150 nonalcoholic fatty liver disease (NAFLD) and insulin resistance, but the mechanisms that initiate the

151 roteins in the liver is sufficient to induce insulin resistance by impairing insulin signaling and gl

152 hat Nrp1 reduction in macrophages instigates insulin resistance by increasing macrophage Nlrp3 inflam

153 glucose, and homeostasis model assessment of insulin resistance] by using family data and a variance

154 Diets promoting obesity and insulin resistance can lead to severe metabolic diseases

155 Hyperglycemia- and hyperinsulinemia-induced insulin resistance causes alterations in cellular bioene

156 th an isolated elevated FAI showed increased insulin resistance compared to those with an isolated sa

157 ulin-stimulated glucose disposal, and muscle insulin resistance confers many negative health outcomes

158 Reversal of insulin resistance could be attributed to reductions in

159 fication of vascular risk factors, including insulin resistance, could improve poststroke cognitive f

160 s complex (TSC) genes and is associated with insulin resistance, decreased glycogen synthase kinase 3

161 t diet, JAK2L mice had hepatic steatosis and insulin resistance despite protection from diet-induced

162 possible explanation for the improvement of insulin resistance/diabetes after gastrointestinal bypas

163 Distinct metabolites were changed with insulin resistance, diet, and between strains.

164 onsistent evidence of glucose intolerance or insulin resistance during pregnancy.

165 earlier onset of adipocyte maturation arrest/insulin resistance during weight gain could be a major f

166 Measures of insulin resistance, dyslipidemia, and diabetes mellitus

167 fed Nrp1(myel-KO) mice displayed accentuated insulin resistance, enhanced systemic inflammation, and

168 erm knockdown of BIM rescued obese mice from insulin resistance, evidenced by reduced fat accumulatio

169 his study evaluated the mechanisms governing insulin resistance, glucose metabolism and lipogenesis i

170 Traditionally, obesity and its correlate, insulin resistance, have been considered the major media

171 resistance (homeostatic model assessment of insulin resistance) (Hedges g = 0.35; 95% CI, 0.14 to 0.

172 pectrometry, homeostasis model assessment of insulin resistance, hepatic IR (Hep-IR; Hep-IR = endogen

173 of fat resulted in a measurable increase in insulin resistance, hepatic triglycerides, and gluconeog

174 to treat obesity-associated fatty liver and insulin resistance.Hepatic steatosis is a common disease

175 with higher homeostatic model assessment of insulin resistance (HOMA-IR) [betaPFOS=0.39; 95% confide

176 the homeostasis model assessment estimate of insulin resistance (HOMA-IR) and liver fibrosis defined

177 onectin, and homeostatic model assessment of insulin resistance (HOMA-IR) in mid-childhood.

178 comes were bodyweight, homoeostatic model of insulin resistance (HOMA-IR), akathisia, and sedation.

179 lesterol, BMI, waist circumference, and HOMA-insulin resistance (HOMA-IR).

180 insulin and homeostasis model assessment of insulin resistance (HOMA-IR).

181 Homeostasis model assessment for insulin resistance (HOMA2-IR) was measured at baseline a

182 changes in fasting glucose, fasting insulin, insulin resistance (homeostasis model assessment of insu

183 = 0.41; 95% CI, 0.09 to 0.72; P = .01), and insulin resistance (homeostatic model assessment of insu

184 t content probably influences both NAFLD and insulin resistance; however, the immediate effects of fa

185 in receptor antagonist S961 to induce severe insulin resistance, hyperglycemia, and ketonemia in mice

186 issue (WAT) and blocked HFD-induced obesity, insulin resistance, hyperlipidemia and hepatic steatosis

187 -like growth factor-1 signalling (IGF-1) and insulin resistance (i.e. decreased insulin/IGF-1) have b

188 into the pathogenic mechanisms of apoE4 and insulin resistance in AD.

189 n to promote adipose tissue inflammation and insulin resistance in animal studies.

190 ino acids (BCAAs), which are associated with insulin resistance in both humans and rodents, modestly

191 oportion of plasma C16:0 was associated with insulin resistance in E4 carriers.

192 ide, the insulin-to-glucagon ratio, and HOMA-insulin resistance in fasted adult DKO pigs and blood gl

193 correlates with indices of inflammation and insulin resistance in humans.

194 FGF21 might be involved in protein-mediated insulin resistance in humans.

195 recently been identified as associated with insulin resistance in humans.

196 epatic steatosis, dyslipidemia, obesity, and insulin resistance in humans.

197 t from metabolically healthy subjects caused insulin resistance in IgG-deficient mice via FcgammaRIIB

198 treatment reversed hypertriglyceridemia and insulin resistance in liver and skeletal muscle.

199 refore, our data elucidate the mechanisms of insulin resistance in LMCs and provide the first evidenc

200 Hence, we hypothesized that insulin resistance in lymphatic muscle cells (LMCs) affe

201 ke behavior, altered glucose metabolism, and insulin resistance in male offspring at adulthood.

202 osition and hypoxia (independent of sex) and insulin resistance in male offspring.

203 rful tool to generate both acute and chronic insulin resistance in mammalian models to elucidate diab

204 ochondrial dysfunction, hepatosteatosis, and insulin resistance in mice.

205 ability during diet-induced obesity promotes insulin resistance in mice.

206 In conclusion, our observation of brain insulin resistance in multiple system atrophy patients a

207 Therefore, brain insulin resistance in obesity may have unfavorable conse

208 arly steps in the insulin signaling cascade, insulin resistance in obesity seems to be largely elicit

209 nce insulin secretion, thereby counteracting insulin resistance in obesity.

210 ves cold tolerance and prevents and reverses insulin resistance in obesity.

211 fate, and suggest a novel strategy to combat insulin resistance in obesity.

212 brief (two weeks) high fat diet (HFD) caused insulin resistance in rat skeletal muscle.

213 4 (RBP4) has been implicated as a driver of insulin resistance in rodents and humans, and it has bec

214 0 prevents aging-associated inflammation and insulin resistance in skeletal muscle.

215 Insulin resistance in tumour endothelial cells produces

216 dy identifies Vps34 as a new drug target for insulin resistance in Type-2 diabetes, in which the unme

217 t serum folate was inversely associated with insulin resistance in U.S. nondiabetic adults.

218 ose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.

219 ize, is the strongest factor associated with insulin resistance in women with polycystic ovary syndro

220 d from offspring mice for lipid profiles and insulin resistance, indirect calorimetry was performed a

221 In the Insulin Resistance Intervention after Stroke (IRIS) tria

222 A secondary analysis was conducted of the Insulin Resistance Intervention After Stroke trial, a do

223 The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrat

224 sms relating sarcopenia and NASH may include insulin resistance (IR) and increased inflammation.

225 Whether individuals with insulin resistance (IR) but without criteria for diabete

226 role of beta-cell dysfunction and peripheral insulin resistance (IR) is well established.

227 rotein catabolism, obesity, and/or increased insulin resistance (IR) or impaired tissue metabolism is

228 E4-associated phenotypes and insulin resistance (IR) share several features and appea

229 metabolism in obesity may lead to increased insulin resistance (IR) that predisposes to these disord

230 dies have linked impaired glucose uptake and insulin resistance (IR) to functional impairment of the

231 mic reticulum (ER) stress, inflammation, and insulin resistance (IR) were studied.

232 ogressive relation among metabolic syndrome, insulin resistance (IR), and dementia has recently been

233 ole in the development of obesity-associated insulin resistance (IR).

234 NAFLD is associated to Insulin Resistance (IR).

235 BMP-9 and conventional markers for MetS and insulin resistance (IR).

236 elminth infections are associated with lower insulin resistance (IR).

237 2 diabetes lies a key metabolic derangement: insulin resistance (IR).

238 Insulin resistance is a hallmark of diabetes and an unme

239 Insulin resistance is a key mediator of obesity-related

240 Insulin resistance is a well-known risk factor for obesi

241 The onset of obesity-associated insulin resistance is due, in part, to the compromise of

242 Insulin resistance is highly prevalent among patients wi

243 own that high-fat diet-induced (HFD-induced) insulin resistance is mitigated in B cell-deficient (Bnu

244 Peripheral insulin resistance is prevented during increased hepatic

245 d and carbohydrate metabolism resulting from insulin resistance leads to hyperglycemia, the hallmark

246 Obesity-associated insulin resistance led to increased susceptibility of fl

247 sulted in higher body weight, development of insulin resistance, lower brain glucose uptake and gluco

248 Low AGE diets decreased insulin resistance (mean difference [MD] -1.3, 95% CI -2

249 between central obesity and MS, and whether insulin resistance mediates the association between ox-L

250 aditional CVD risk factors, kidney function, insulin resistance, MRI and dual-energy x-ray absorptiom

251 clude various aspects of metabolism, such as insulin resistance, muscle wasting, mitochondrial dysfun

252 lating miR-122 was associated with prevalent insulin resistance, obesity, metabolic syndrome, type 2

253 his function predisposes animals to systemic insulin resistance, overeating, and obesity.

254 showed a metabolic phenotype (p < 0.05) and insulin resistance (p < 0.001).

255 0.021) and homeostatic model assessment for insulin resistance (P = 0.027) at follow-up independent

256 st levels of homeostatic model assessment of insulin resistance (P<0.001 versus low group for both se

257 identify 53 genomic regions associated with insulin resistance phenotypes (higher fasting insulin le

258 sporter GLUT4 are associated with peripheral insulin resistance, preclinical diabetes, and progressio

259 significantly lowers BP in individuals with insulin resistance, prediabetes, or other noncommunicabl

260 echanistic linkage between folate status and insulin resistance remains unclear with very limited exp

261 rred by 17beta-estradiol against obesity and insulin resistance requires ERalpha-AF2 but not ERalpha-

262 In some cases, NAFLD is also accompanied by insulin resistance, resulting in metabolic dysfunction.

263 Insulin resistance results from an intricate interaction

264 rd Asian Pacific Program in Hypertension and Insulin Resistance (SAPPHIRe) to investigate association

265 tant based on a Homeostasis Model Assessment-Insulin Resistance score >3.0.

266 glycemia, homeostasis model of assessment of insulin resistance, serum ferritin, lipid profile, and l

267 Onset of insulin resistance significantly impaired glucose uptake

268 ibility to obesity, glucose intolerance, and insulin resistance specifically in HFD-fed male mice.

269 ption for treatment of patients with extreme insulin-resistance syndromes.

270 Hepatic insulin resistance, synergistically with lowered insulin

271 While Plenish induced less insulin resistance than conventional soybean oil, it res

272 e established features of obesity-associated insulin resistance, the intestine is emerging as a new s

273 n of cellular energy metabolism resulting in insulin resistance thereby leading to diabetes.

274 emic stroke or transient ischemic attack and insulin resistance, those at higher risk for future stro

275 New findings also connect insulin resistance to extensive metabolic cross-talk bet

276 Exercise bypasses insulin resistance to increase glucose uptake in skeleta

277 downstream of InR at potential mediators of insulin resistance, transcriptome sequencing (RNA-seq) s

278 waist circumference, hemoglobin A1c (HbA1c), insulin resistance, triglycerides, HDL cholesterol (HDL-

279 s a central pathologic component of obesity, insulin resistance, type 2 diabetes and associated morbi

280 strophy exhibit hypertriglyceridemia, severe insulin resistance, type 2 diabetes, and nonalcoholic st

281 e in related health complications, including insulin resistance, type 2 diabetes, cardiovascular dise

282 ted anti-incretin effect could contribute to insulin resistance/type 2 diabetes, whereas reduction of

283 resistant to hepatic steatosis, obesity and insulin resistance under a lipogenic diet.

284 rial dysfunction, steatosis development, and insulin resistance under high fat diet.

285 gulate myocyte metabolism, and contribute to insulin resistance via paracrine effects.

286 Their selective, liver-specific insulin resistance was associated with increased C18:1-d

287 These results revealed HFD-induced insulin resistance was attributable to fiber type select

288 Of note, the hepatic insulin resistance was not associated with increased lev

289 ich alterations in Nat2 activity might cause insulin resistance, we examined murine ortholog Nat1 kno

290 Hepatic and muscle insulin resistance were associated with marked increases

291 teers and eight severely obese subjects with insulin resistance were studied.

292 tal muscle metabolic flexibility and induces insulin resistance, whereas exercise training exerts pos

293 Type 2 diabetes is characterized by insulin resistance, which arises from malfunctions in th

294 Nat1 KO mice manifested whole-body insulin resistance, which could be attributed to reduced

295 siological tau loss-of-function favors brain insulin resistance, which is instrumental for cognitive

296 own adipose tissues, glucose intolerance and insulin resistance while exhibiting suppressed aromatase

297 ce were better protected against obesity and insulin resistance with increased circulating fibroblast

298 HFD-fed mice exhibited insulin resistance with reduced levels of Nrp1 in macrop

299 Among patients with insulin resistance without diabetes mellitus, pioglitazo

300 ischemic attack within 180 days of entry and insulin resistance without type 1 or type 2 diabetes.